Bioanalytical Systems, Inc. -- BASI -- Shifts Management, Focuses on Vision.

Business Editors & Health/Medical Writers

BIOWIRE2K

WEST LAFAYETTE, Ind.--(BW HealthWire)--April 6, 2000

Bioanalytical Systems, Inc. (Nasdaq:BASI), provider of contract research services and instrumentation to the pharmaceutical industry, has realigned its management team.

"Growth since our 1997 public offering and a clear vision of our future make it appropriate to reassign and expand on responsibilities of several key members of our management team," said Chairman and CEO Peter T. Kissinger, Ph.D.

Craig S. Bruntlett, Ph.D. has been promoted to Senior Vice President, International Sales. Dr. Bruntlett, who served as VP of the Electrochemical Products Division since 1983, joined BAS as a senior research chemist after receiving a Ph.D. in Chemistry from Purdue University.

Candice B. Kissinger was named Senior Vice President, Marketing, and will work to strengthen corporate marketing strategy and tactics, particularly through implementation of BAS' accelerating e-commerce initiative. Formerly the VP of International Sales and Marketing, Ms. Kissinger established BAS' global position in analytical chemical instrumentation. Ms. Kissinger will continue as a Director and Secretary of the corporation.

"The growing complexity and clear pharmaceutical market focus of our business present an opportunity to separate these functions. This move will enable us to take full advantage of the rapidly evolving global web economy through Dr. Bruntlett and Ms. Kissinger," said Pete Kissinger.

Michael P. Silvon, Ph.D., VP Business Development, will assume additional responsibilities as General Manager of BAS Evansville, the newly acquired preclinical contract research facility, and BAS Vetronics, the company's veterinary physiology monitoring business. Dr. Silvon joined BAS in 1997, having held senior business management positions in the specialty chemicals industry.

BAS manufacturing operations will now report through Douglas P. Wieten, VP Finance. "My best contributions to BAS future will come from outside, from strategic corporate relationships and from strengthening shareholder value," Dr. Kissinger commented. "Doug is respected by our operations people and is a skilled mentor. Under Doug, I expect manufacturing to continue improving processes begun on our trek toward ISO 9000 qualification."

BAS is a knowledge business. The BAS research team has been recognized for its contributions to understanding the underlying causes of diseases like diabetes, osteoporosis, HIV, adrenal cancer, and hypertension. In addition to toxicology and bioanalytical services, BAS is an industry leader in instrument systems for monitoring in vivo biochemistry and physiology. Clients use these systems in new drug development, toxicology, and in cancer, addiction and behavioral research. Visit www.bioanalytical.com and www.culex.net for more about BAS.

This release contains forward-looking statements that are subject to risks and uncertainties, including but not limited to risks and uncertainties related to the development of products and services, changes in technology, strategy, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.